MYC and pancreatic neoplasm: To evaluate if the mevalonate pathway could contribute to pancreatic cancer cell survival/proliferation in cells treated by c-Myc inhibitor, we assessed cell viability and the capacity to form colonies of these cells undergoing such treatment in the presence or in the absence of mevalonate.